Brought to you by 
IDM, Oxford BioMedica develop cell therapy programs
05 Oct 2000
Executive Summary
Immuno-Designed Molecules (cell and gene therapy) and Oxford BioMedica (immunotherapy via gene delivery) will jointly develop new vaccines for cancer and other diseases using IDM's core cell therapy technology that incorporates gene therapy.
Deal Industry
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Site Specific
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
IDM, Oxford BioMedica develop cell therapy programs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice